Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apothecon To Continue As Bristol Unit After Sale Of Generics To Novartis

Executive Summary

Bristol Myers-Squibb will continue to market generic drugs internationally and its branded generics in the U.S. following the sale of U.S. rights to its Apothecon subsidiary's line of finished generic drugs to Novartis.

You may also be interested in...



Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist

Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone

Novartis Pursuing Generic Biologics; Says Brand And Generic Lines Co-Exist

Novartis is positioning itself at the forefront of companies seeking approval of generic biologics with a pending application for human growth hormone

AHP Exiting Oral Generics Business; K-Dur Settlement With FTC Near

American Home Products is phasing out its oral solid dosage form generic drug business, the company said in documents filed as part of the Federal Trade Commission suit against ESI Lederle

Related Content

UsernamePublicRestriction

Register

PS037038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel